India, Oct. 6 -- Saluda Medical (SLD.AX) said it has completed the full U.S. commercial release of its CAP24 Surgical Paddle Lead following FDA approval earlier this year.
CAP24 is now broadly available to neurosurgery and orthopedic spine practices across the U.S., following a limited market release at selected centers.
During the limited release, physicians provided positive feedback on the device's performance and integration into clinical practice.
CAP24 is designed for use with Saluda's Evoke System and enables physiologic, dose-controlled closed-loop therapy by measuring each patient's neural response and adapting stimulation with each pulse.
The surgical paddle lead features a low-profile, anatomically contoured design intended t...